RALPH NIVEN - 22 Jan 2024 Form 4 Insider Report for Aerovate Therapeutics, Inc. (JBIO)

Role
CHIEF SCIENTIFIC OFFICER
Signature
/s/ George A. Eldridge, Attorney-in-Fact
Issuer symbol
JBIO
Transactions as of
22 Jan 2024
Net transactions value
$0
Form type
4
Filing time
24 Jan 2024, 18:00:27 UTC
Previous filing
08 Jan 2024
Next filing
07 Feb 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTE Stock Option (Right to Buy) Award $0 +66,586 $0.000000 66,586 22 Jan 2024 Common Stock 66,586 $20.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vesting on February 22, 2024.